title: Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets.
abstract: The aim of this study was to investigate the efficacy, receptor specificity, and site of action of Delta9-tetrahydrocannabinol (THC) as an antiemetic in the ferret. THC (0.05-1 mg/kg ip) dose-dependently inhibited the emetic actions of cisplatin. The ED50 for retching was approximately 0.1 mg/kg and for vomiting was 0.05 mg/kg. A specific cannabinoid (CB)1 receptor antagonist SR-141716A (5 mg/kg ip) reversed the effect of THC, whereas the CB2 receptor antagonist SR-144528 (5 mg/kg ip) was ineffective. THC applied to the surface of the brain stem was sufficient to inhibit emesis induced by intragastric hypertonic saline. The site of action of THC in the brain stem was further assessed using Fos immunohistochemistry. Fos expression induced by cisplatin in the dorsal motor nucleus of the vagus (DMNX) and the medial subnucleus of the nucleus of the solitary tract (NTS), but not other subnuclei of the NTS, was significantly reduced by THC rostral to obex. At the level of the obex, THC reduced Fos expression in the area postrema and the dorsal subnucleus of the NTS. The highest density of CB1 receptor immunoreactivity was found in the DMNX and the medial subnucleus of the NTS. Lower densities were observed in the area postrema and dorsal subnucleus of the NTS. Caudal to obex, there was moderate density of staining in the commissural subnucleus of the NTS. These results show that THC selectively acts at CB1 receptors to reduce neuronal activation in response to emetic stimuli in specific regions of the dorsal vagal complex.
authors.affiliation: Department of Physiology and Biophysics, University of Calgary, Calgary, Alberta, Canada T2N 4N1.
authors.forename: Marja D
authors.initials: MD
authors.lastname: Van Sickle
authors.forename: Lorraine D
authors.initials: LD
authors.lastname: Oland
authors.forename: Ken
authors.initials: K
authors.lastname: Mackie
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Davison
authors.forename: Keith A
authors.initials: KA
authors.lastname: Sharkey
mesh_terms: D000818:Animals; D000932:Antiemetics / Q000494:pharmacology*; D031608:Area Postrema / Q000378:metabolism; D002945:Cisplatin / Q000494:pharmacology; D013759:Dronabinol / Q000494:pharmacology*; D005289:Ferrets; D008526:Medulla Oblongata / Q000378:metabolism*; D016760:Proto-Oncogene Proteins c-fos / Q000037:antagonists & inhibitors / Q000378:metabolism; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000187:drug effects* / Q000502:physiology; D014018:Tissue Distribution; D014630:Vagus Nerve / Q000502:physiology*; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D016760:Proto-Oncogene Proteins c-fos; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D013759:Dronabinol; D002945:Cisplatin